MYRIAD GENETICS INC (MYGN) Stock News
NASDAQ:MYGN - Nasdaq - US62855J1043 - Common Stock - Currency: USD
MYGN Latest News, Press Relases and Analysis
What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know.
What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know.
Myriad Genetics Included in Forbes America’s Best Employers 2025 List
Myriad Genetics has been named on the Forbes list of America’s Best Employers 2025....
Myriad Genetics Included in Forbes America’s Best Employers 2025 List
Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025
Myriad Genetics will hold its fourth quarter and full year 2024 earnings conference call at 4:30 pm ET on Monday, Feb. 24, 2025....
Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025
Management will participate in three upcoming investor healthcare conferences
3 Reasons to Sell MYGN and 1 Stock to Buy Instead
Myriad Genetics’s stock price has taken a beating over the past six months, shedding 47.8% of its value and falling to $14.75 per share. This might have investors contemplating their next move.
3 Reasons to Sell MYGN and 1 Stock to Buy Instead
Myriad Genetics’s stock price has taken a beating over the past six months, shedding 47.8% of its value and falling to $14.75 per share. This might have investors contemplating their next move.
Mentions: MSFT
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
Myriad Genetics and CancerCARE for Life announced an agreement designed to enhance education and access to hereditary cancer testing....
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
Myriad Genetics announces it was granted two new patents for its Molecular Residual Disease (MRD) assay....
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
Myriad Genetics and Lumea have signed an agreement to enhance access to the Prolaris and MyRisk Hereditary Cancer tests through BxLink integration....
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
Myriad Genetics will unveil groundbreaking eight weeks’ gestation NIPT study results at the annual SMFM conference....
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
Opening plenary session features latest fetal fraction amplification research
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
Myriad Genetics launches a new educational website providing information about reproductive and prenatal genetic testing called
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
Myriad Genetics announced a hereditary cancer risk assessment program study was published in Obstetrics & Gynecology (also known as The Green Journal)....
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
Study showed online screening tool and patient education improved genetic testing completion rate
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance
Myriad Genetics announces select preliminary fourth quarter and full year 2024 financial results and introduces full year 2025 financial guidance....
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
Myriad Genetics announced it signed an agreement with sports broadcaster Hannah Storm to promote the importance of knowing family cancer history. ...
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Paul J. Diaz, President and CEO, and Sam Raha, COO, Myriad Genetics, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference....
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Paul J. Diaz, President and CEO, and Sam Raha, COO, Myriad Genetics, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference....
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report
Myriad Genetics released its Quality, Innovation, and Corporate Responsibility Report....
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
Myriad Genetics announced a MyRisk® Hereditary Cancer Test with RiskScore® study was named as one of the top 10 significant advances in genomic medicine....
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick Model
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
Myriad Genetics provides update on discussions with UnitedHealthcare regarding medical policy for pharmacogenetic testing....
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
Myriad Genetics announced the election of Mark S. Davis to its Board of Director, effective immediately, expanding the Board from eight to nine members....